Polyphenols targeting diabetes via the AMP-activated protein kinase pathway; future approach to drug discovery.
Saeideh MomtazArmin Salek-MaghsoudiAmir Hossein AbdolghaffariEghbal JasemiShamsali RezazadehShokoufeh HassaniMojtaba ZiaeeMohammad AbdollahiSahar BehzadSeyed Mohammad NabaviPublished in: Critical reviews in clinical laboratory sciences (2019)
Regarding the widespread progression of diabetes, its related complications and detrimental effects on human health, investigations on this subject seems compulsory. AMP-activated protein kinase (AMPK) is a serine/threonine kinase and a key player in energy metabolism regulation. AMPK is also considered as a prime target for pharmaceutical and therapeutic studies on disorders such as diabetes, metabolic syndrome and obesity, where the body energy homeostasis is imbalanced. Following the activation of AMPK (physiological or pharmacological), a cascade of metabolic events that improve metabolic health is triggered. While there are several publications on this subject, this is the first report that has focused solely on polyphenols targeting diabetes via AMPK pathway. The multiple characteristics of polyphenolic compounds and their favorable influence on diabetes pathogenesis, as well as their intersections with the AMPK signaling pathway, indicate that these compounds have a beneficial effect on the regulation of glucose homeostasis. PPs could potentially occupy a significant position in the future anti-diabetic drug market.
Keyphrases
- protein kinase
- type diabetes
- cardiovascular disease
- glycemic control
- metabolic syndrome
- human health
- signaling pathway
- drug discovery
- insulin resistance
- healthcare
- public health
- mental health
- blood glucose
- climate change
- cancer therapy
- weight loss
- body mass index
- oxidative stress
- blood pressure
- social media
- adipose tissue
- physical activity
- endoplasmic reticulum stress
- emergency department
- drug induced
- tyrosine kinase
- cardiovascular risk factors